EIGR stock forecast
Our latest prediction for Eiger BioPharmaceuticals, Inc.'s stock price was made on the April 22, 2019 when the stock price was at 10.97$.
In the short term (2weeks), EIGR's stock price should outperform the market by 2.30%. During that period the price should oscillate between -8.94% and +13.24%.
In the medium term (3months), EIGR's stock price should outperform the market by 1.87%. During that period the price should oscillate between -21.15% and +33.81%.Get email alerts
Create a solid portfolio with EIGR
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.30$ per share.
The book value per share is 3.46$
Three months stock forecastApril 22, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|